|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastric calcifying fibrous tumor removed by endoscopic submucosal dissection显示文摘The World Health Organization describes calcifying fibrous tumors(CFTs) as rare, benign lesions characterized by hypocellular, densely hyalinized collagenization with lymphoplasmacytic infiltration. These tumors rarely involve the gastrointestinal(GI) tract. A routine endoscopic upper gastrointestinal screen detected a 10-mm submucosal tumor(SMT) in the lesser curvature of the lower corpus of the stomach of an apparently healthy, 37-year-old woman with no history of Helicobacter pylori infection. Endoscopic ultrasonography(EUS) localized the internally isoechoic, homogeneous SMT mainly within the submucosa. Malignancy was ruled out using endoscopic submucosal dissection(ESD). A pathological examination confirmed complete resection of the SMT, and defined a hypocellular, spindle-cell tumor with a densely hyalinized, collagenous matrix, scattered lymphoplasmacytic aggregates as well as a few psammomatous, dystrophic calcified foci. The mass was immunohistochemically positive for vimentin and negative for CD117(c-kit protein), CD34, desmin, smooth muscle actin(SMA) and S100. Therefore, the histological findings were characteristic of a CFT. To date, CFT resection by ESD has not been described. This is the first case report of a gastric calcifying fibrous tumor being completely resected by ESD after endoscopic ultrasonography. | Naotaka Ogasawara Shinya Izawa Mari Mizuno Atsushi Tanabe Tomonori Ozeki Hisatsugu Noda Emiko Takahashi Makoto Sasaki Toyoharu Yokoi Kunio Kasugai | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，9： | 8 |
| 2 | Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant,non-erosive esophagitis显示文摘AIM:To evaluate the efficacy,safety,and long-term outcomes of endoluminal gastroplication(ELGP) in patients with proton pump inhibitor(PPI)-resistant,nonerosive reflux disease(NERD).METHODS:The subjects were NERD patients,diagnosed by upper endoscopy before PPI use,who had symptoms such as heartburn or reflux sensations two or more times a week even after 8 wk of full-dose PPI treatment.Prior to ELGP,while continuing full-dose PPI medication,patients' symptoms and quality of life(QOL) were assessed using the questionnaire for the diagnosis of reflux disease,the frequency scale for symptoms of gastro-esophageal reflux disease(FSSG),gastrointestinal symptoms rating scale,a 36-item short-form.In addition,24-h esophageal pH monitoring or 24-h intraesophageal pH/impedance(MII-pH) monitoring was performed.The Bard EndoCinch TM was used for ELGP,and 2 or 3 plications were made.After ELGP,all acid reducers were temporarily discontinued,and medication was resumed depending on the development and severity of symptoms.Three mo after ELGP,symptoms,QOL,pH or MII-pH monitoring,number of plications,and PPI medication were evaluated.Further,symptoms,number of plications,and PPI medication were evaluated 12 mo after ELGP to investigate long-term effects.RESULTS:The mean FSSG score decreased significantly from before ELGP to 3 and 12 mo after ELGP(19.1 ± 10.5 to 10.3 ± 7.4 and 9.3 ± 9.9,P < 0.05,respectively).The total number of plications decreased gradually at 3 and 12 mo after ELGP(2.4 ± 0.8 to 1.2 ± 0.8 and 0.8 ± 1.0,P < 0.05,respectively).The FSSG scores in cases with no remaining plications and in cases with one or more remaining plications were 4.4 and 2.7,respectively,after 3 mo,and 2.0 and 2.8,respectively,after 12 mo,showing no correlation to plication loss.On pH monitoring,there was no difference in the percent time pH < 4 from before ELGP to 3 mo after.Impedance monitoring revealed no changes in the number of reflux episodes or the symptom index for reflux events from before ELGP to 3 mo after,but the symptom sensitivity index decreased significantly 3 mo after ELGP(16.1 ± 12.9 to 3.9 ± 8.3,P < 0.01).At 3 mo after ELGP,6 patients(31.6%) had reduced their PPI medication by 50% or more,and 11 patients(57.9%) were able to discontinue PPI medication altogether.After 12 mo,3 patients(16.7%) were able to reduce the amount of PPI medication by 50% or more,and 12 patients(66.7%) were able to discontinue PPI medication altogether.A high percentage of cases with remaining plications had discontinued PPIs medication after 3 mo,but there was no difference after 12 mo.No serious complications were observed in this study.CONCLUSION:ELGP was safe,resulted in significant improvement in subjective symptoms,and allowed less medication to be used over the long term in patients with PPI-refractory NERD. | Kentaro Tokudome Yasushi Funaki Makoto Sasaki Shinya Izawa Yasuhiro Tamura Akihito Iida Naotaka Ogasawara Toshihiro Konagaya Yoshifumi Tokura Kunio Kasugai | 2012 | World Journal of Gastroenterology2012，18，41： | 5 |
| 3 | Pathophysiology of functional heartburn based on Rome Ⅲ criteria in Japanese patients显示文摘AIM:To investigate the pathophysiology of functional heartburn(FH) in Japanese patients.METHODS:A total of 111 patients with proton pump inhibitor(PPI)-refractory non-erosive gastroesophageal reflux disease underwent intraesophageal pressure testing and 24-h multichannel intraluminal impedancep H(24MII-p H) testing.The patients also completed several questionnaires while they were receiving the PPI treatment, including the questionnaire for the diagnosis of reflux disease(QUEST), the frequency scale for the symptoms of gastroesophageal reflux disease(FSSG), the gastrointestinal symptoms rating scale(GSRS), SF-36, and the Cornell Medical Index(CMI).The subjects were classified into FH and endoscopy-negative reflux disease(ENRD) groups based on the Rome Ⅲ criteria.RESULTS:Thirty-three patients with esophageal motility disorder were excluded from this study, while 22 patients with abnormal esophageal acid exposure time(p H-POS) and 34 with hypersensitive esophagus(HE) were included in the ENRD group.The FH group included 22 patients with no reflux involvement.Sex, age, and body mass index did not differ significantly between the groups.The mean SF-36 values were < 50(normal) for all scales in these groups, with no significant differences.The GSRS scores in these groups were not different and showed overlap with other gastrointestinal symptoms.The QUEST and the FSSG scores did not differ significantly between the groups.Neuroticism was diagnosed using the CMI questionnaire in 17 of the 78 included subjects within the p H-POS(n=4),HE(n=8),and FH(n=5)groups,with no significant differences.CONCLUSION:Clinical characteristics of the FH and PPI-refractory ENRD groups were similar.Therefore,esophageal function should be examined via manometry and 24MII-p H testing to differentiate between them. | Yasuhiro Tamura Yasushi Funaki Shinya Izawa Akihito Iida Yoshiharu Yamaguchi Kazunori Adachi Naotaka Ogasawara Makoto Sasaki Hiroshi Kaneko Kunio Kasugai | 2015 | World Journal of Gastroenterology2015，21，16： | 4 |
| 4 | Inhibition of gastric perception of mild distention by omeprazole in volunteers显示文摘AIM:To evaluate the effects of omeprazole on gastric mechanosensitivity in humans. METHODS:A double lumen polyvinyl tube with a plastic bag was introduced into the stomach of healthy volunteers under fluorography and connected to a barostat device. Subjects were then positioned so they were sitting comfortably, and the minimal distending pressure (MDP) was determined after a 30-min adaptation period. Isobaric distensions were performed in stepwise increments of 2 mmHg (2 min each) starting from the MDP. Subjects were instructed to score feel-ings at the end of every step using a graphic rating scale:0, no perception; 1, weak/vague; 2, weak but significant; 3, moderate/vague; 4, moderate but signifi-cant; 5, severe discomfort; and 6, unbearable pain. After this first test, subjects received omeprazole (20 mg, after dinner) once daily for 1 wk. A second test was performed on the last day of treatment. RESULTS:No adverse effects were observed. Mean MDP before and after treatment was 6.3 ± 0.3 mmHg and 6.2 ± 0.5 mmHg, respectively. One subject before and 2 after treatment did not reach a score of 6 at the maximum bag volume of 750 mL. After omeprazole, there was a significant increase in the distension pres-sure required to reach scores of 1 (P = 0.019) and 2 (P = 0.017) as compared to baseline. There were no changes in pressure required to reach the other scores after treatment. Two subjects before and one after omeprazole rated their abdominal feeling < 1 at MDP, and mean (± SE) abdominal discomfort scores at MDP were 0.13 ± 0.09 and 0.04 ± 0.04, respectively. Mean scores induced by each MDP + 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 (mmHg) were 1.1 ± 0.3, 2.0 ± 0.4, 2.9 ± 0.5, 3.3 ± 0.4, 4.6 ± 0.3, 5.2 ± 0.3, 5.5 ± 0.2, 5.5 ± 0.3, 5.7 ± 0.3, and 5.4, respectively. After omepra-zole, abdominal feeling scores for the same incremental pressures over MDP were 0.3 ± 0.1, 0.8 ± 0.1, 2.0 ± 0.4, 2.8 ± 0.4, 3.8 ± 0.4, 4.6 ± 0.4, 4.9 ± 0.3, 5.4 ± 0.4, 5.2 ± 0.6, and 5.0 ± 1.0, respectively. A signif- icant decrease in feeling score was observed at intrabag pressures of MDP + 2 mmHg (P = 0.028) and + 4 mmHg (P = 0.013), respectively, after omeprazole. No significant score changes were observed at pres-sures ≥ MDP + 6 mmHg. CONCLUSION:Although the precise mechanisms are undetermined, the present study demonstrated that omeprazole decreases mechanosensitivity to mild gastric distension. | Akihito Iida Hiroshi Kaneko Toshihiro Konagaya Yasushi Funaki Kentaro Tokudome Shinya Izawa Yasuhiro Tamura Mari Mizuno Naotaka Ogasawara Makoto Sasaki Kunio Kasugai | 2012 | World Journal of Gastroenterology2012，18，39： | 3 |
| 5 | Transarterial chemo- therapy alone versus transarterial chemoembolization for hepato- cellular carcinoma:a randomized phase llI trial 显示文摘 | Okusaka T Kasugai H Shioyama Y | 2009 | J Hepatol2009，51，6： | 1 |
| 6 | Outcome of 51 nonmalignant nodules in the liver: usefulness of aspiration cytology for diagnosis of dysplastic nodules显示文摘 | Kaji I Kasugai H Takenaka A | 2004 | J Exp Clin Cancer Res2004，23，3： | 1 |
| 7 | Ground-Glass Opacity on Thin-Section CT:Value in Differentiating Subtypes of Adenocarcinoma of the Lung显示文摘 | Kuriyama K Seto M Kasugai T | 1999 | AJR1999，173，2： | 1 |
| 8 | Infection of Nippostrongylus brasiliensis induces development of mucosal-type but not connective tissue-type mast cells in genetically mast cell-deficient Ws/Ws rats显示文摘 | Arizono N Kasugai T Yamada M | 1993 | Blood1993，81，： | 1 |
| 9 | Behavior of bone marrow cells cultured on three different coatings of gel-derived bioactive glass-ceramics at early stages of cell differentiation显示文摘 | Laczka-Osyczka A Lazka M Kasugai S | 1998 | J Biomed Mater Res1998，42，： | 1 |
| 10 | Crystalline lightchain deposition and amyloidosis in the thyroid gland and kidneys of a patient with myeloma显示文摘 | Hirota S Miyamoto M Kasugai T | 1990 | Arch Pathol Lab Med1990，114，4： | 1 |
| 11 | Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients显示文摘 | Kasugai H Osaki Y Oka H | 2007 | Oneology2007，721，： | 1 |
| 12 | An efficient mechanical polishing method for diamond-coated inserts and testing of their performance显示文摘 | Murakawa M Takeuchi S Alahelisten A Kasugai M | 1996 | Surface and Coating Technology1996，，8687： | 1 |
| 13 | Dental implant treatment to osteoporosis patients 显示文摘 | Kasugai S | 2006 | Clin Calcium2006，16，2： | 1 |
| 14 | Induced osteogenesis using a new pe- riosteal distractor显示文摘 | Zakariao M Kasugai S | 2012 | J Oral Maxillofac Surg2012，70，3： | 1 |
| 15 | Evaluation of a biodegradable novel pericsteal distractor 显示文摘 | Zakaria O Kon K Kasugai S | 2012 | J Biomed Mater Res B Appl Biomater2012，100，3： | 1 |
| 16 | A new approach to chemoembolization therapy for hepatoma using ethiodized oil,cisplation and gelatin sponge显示文摘 | Sasaki Y Imaoka S Kasugai H | 1987 | Cancer1987，60，6： | 1 |
| 17 | A clinical and radiologic study of primary liver-cancer associated with extrahepatic primary-cancer 显示文摘 | Takayasu K Kasugai H Ikeya S | 1992 | Cancer1992，69，1： | 1 |
| 18 | A randomized phase Ⅱ trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma显示文摘 | Okusaka T Kasugai H Ishii H | 2012 | Invest New Drugs2012，30，5： | 1 |
| 19 | Steady-state operation of 170GHz-1MW gyrotron for ITER显示文摘 | Kasugai A Sakamoto K Takahashi K | 2008 | Nuclear Fusion2008，48，05： | 1 |
| 20 | Severe complications of ra-diofrequency ablation therapy for hepatocellular carcinoma:an analysis of 3,891 ablations in 2,614patients显示文摘 | Kasugai H Osaki Y Oka H | | 0，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员